Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 16/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31676491 | 0.89 | SLC6A9 (0.59) | SLC6A9SLC6A5 | |
| SCHEMBL3230781 | 0.89 | SLC6A9 (0.59) | SLC6A9SLC6A5 | |
| SCHEMBL13780494 | 0.89 | SLC6A9 (0.59) | SLC6A9SLC6A5 | |
| SCHEMBL3030343 | 0.88 | SLC6A9 (0.46) | SLC6A9SLC6A5CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL3038506 | 0.88 | SLC6A9 (0.46) | SLC6A9SLC6A5CYP2C19CYP2C9 | |
| SCHEMBL3034321 | 0.88 | SLC6A9 (0.49) | SLC6A9SLC6A5ALDH1A1 | |
| SCHEMBL3034261 | 0.86 | SLC6A9 (0.44) | SLC6A9SLC6A5ALDH1A1 | |
| SCHEMBL3030679 | 0.85 | SLC6A2 (0.45) | SLC6A9SLC6A5 | |
| SCHEMBL3044646 | 0.85 | SLC6A9 (0.44) | SLC6A9SLC6A5CYP2C19CYP2C9HDAC4 | |
| SCHEMBL3236708 | 0.84 | SLC6A9 (0.48) | SLC6A9SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| WO-2006067414-A2 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | SLC18A2, SLC6A5, SLC1A2 | SLC6A9 13/4885SLC6A5 2/4885LMNA 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.